The blood grouping reagents for extended phenotype testing cover more than 99 percent of the most commonly tested blood-group antigens.
The assay can also be used to assess a broad range of metabolic conditions, including pancreatic tumors, liver disease, acromegaly, and others.
The arrangement will allow Illumina to market and promote Kailos' research solutions for pharmacogenetic target enrichment.
Kits with the affected products may not be able to fully extract nucleic acids from samples and detect infection or provide a correct diagnosis.
The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.
